Illumina Licenses Orchid Cellmark's Nucleotide Extension IP | GenomeWeb

NEW YORK (GenomeWeb News) – Orchid Cellmark has licensed part of its diagnostic and forensics intellectual property portfolio to Illumina in exchange in for an upfront fee, potential milestone payments, and royalties.

The license for Orchid's single base nucleotide extension technology includes an $850,000 license fee, a potential $150,000 in milestone payments, and royalties from Illumina through any subcontracting agreements. Orchid also will be able to buy certain Illumina products utilizing the patents as a preferred customer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.